Column Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Column Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$19.8K	Hold	57	–	–	﹤0.01%	433
2023 Q2	$20.1K	Hold	57	–	–	﹤0.01%	438
2023 Q1	$18K	Sell	57 -6	-10%	-$1.8K	﹤0.01%	460
2022 Q4	$18.2K	Buy	63 +6	+11%	+$1.83K	﹤0.01%	433
2022 Q3	$17K	Hold	57	–	–	﹤0.01%	410
2022 Q2	$16K	Hold	57	–	–	﹤0.01%	416
2022 Q1	$15K	Sell	57 -6	-10%	-$1.42K	﹤0.01%	446
2021 Q4	$14K	Sell	63 -114	-64%	-$22.2K	﹤0.01%	476
2021 Q3	$32K	Hold	177	–	–	0.01%	333
2021 Q2	$36K	Hold	177	–	–	0.01%	322
2021 Q1	$38K	Buy	177 +35	+25%	+$7.69K	0.01%	308
2020 Q4	$34K	Hold	142	–	–	0.01%	322
2020 Q3	$39K	Hold	142	–	–	0.01%	286
2020 Q2	$41K	Buy	142 +53	+60%	+$14.4K	0.01%	280
2020 Q1	$21K	Buy	89 +41	+85%	+$9.4K	0.01%	307
2019 Q4	$10K	Buy	+48	New	+$9.71K	0.01%	452

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Column Capital Advisors's VRTX Position: Q3 2023 in Review

Column Capital Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2023 at 57 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #433.

Column Capital Advisors first reported a position in VRTX in Q4 2019 and has held it in 16 quarters since. The position peaked at $41K in Q2 2020. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Column Capital Advisors held 57 shares of Vertex Pharmaceuticals worth $19.8K as of Q3 2023.
Column Capital Advisors left its Vertex Pharmaceuticals share count unchanged in Q3 2023.
Vertex Pharmaceuticals made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #433 holding.
Column Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
Column Capital Advisors's Vertex Pharmaceuticals position peaked at $41K in Q2 2020.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.